Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Global Market for Mature Biotech – What’s hot, what’s not, what’s next by 2021?

Thursday, December 1, 2016 5:10
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Mature Biotech Market analysis is provided for global market including development trends by regions, competitive analysis of the Mature Biotech market. Mature Biotech Industry report focuses on the major drivers and restraints for the key players.

“Mature Biotech Outlook & Forecase: New Therapy Ventures Pave The Way For Success” report speaks about the manufacturing process. The process is analysed thoroughly with respect four points Manufacturers, regional analysis, Segment by Type and Segment by Applications and the actual process of whole Mature Biotech industry.

Browse More Information of Mature Biotech Market Research Report @ http://www.absolutereports.com/10437981 

All biotech companies – Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies have been able to select therapy/niche indication where the high treatment cost justifies the need.

REGN, ALXN, and VRTX have transformed into a large-cap mature biotech companies. Whether these three will be acquired or will remain independent and evolve in next giant is still a question, but both the cases present a good investment opportunity for those who willing to hold them for next five years.
Ask Sample PDF @ http://www.absolutereports.com/enquiry/request-sample/10437981

While large pharma companies are active in M&A deals, the Mature biotech companies are sticking to its core expertise and venturing into unexplored/new therapy; e.g., GILD in anti-cancer and BIIB for hemophilia. Alike small molecule generics, biosimilar will also get easier and getting similar pace of recognition in coming years; where AMGN, BIIB already started investing in this space and can emerge as a big player in coming years.

REGN, ALXN, and VRTX have transformed into a large-cap mature biotech companies. Whether these three will be acquired or will remain independent and evolve in next giant is still a question, but both the cases present a good investment opportunity for those who willing to hold them for next five years. GILD has announced the dividend payment and now all eyes will be on CELG and BIIB

Inquire More Details of Mature Biotech Market Research Report @ http://www.absolutereports.com/enquiry/pre-order-enquiry/10437981

Detailed TOC of Mature Biotech Market Research Report:
1. Acorda Therapeutics – Neurological Pipeline Getting Bigger
• Key Pipeline Drugs
a. CVT -301 (PhIII, OFF episodes of Parkinson’s disease)
b. Dalfampridine (PhIII, post-stroke walking deficits)
c. rHIgM22 (Remyelinating mAb, PhI)
d. Glial Growth Factor 2 (neuregulin, PhI, GGF2)
• Other Programs in the Pipeline – Future Uncertain

2. Alexion Pharma – Pipeline Maturity will witness a Strong 2015 for ALXN
• Asfotase alfa (hypophosphatasia, HPP, R) on Track 
• Soliris in PNH and aHUS: Growth to Continue
• SOLIRIS BEYOND PNH AND aHUS
• Beyond Soliris
• Other PhII Programs
• Messenger RNA Therapeutics platform from Moderna

3. Amgen – Focus On New Biologics For Larger Market And Exploiting Biologics’ Manufacturing Experience For Biosimilars Gain
• Newly Marketed Product: Future Growth
a. Kyprolis
b. BLINCYTO
• Key Pipeline Products and Development
a. Evolocumab (R, PCSK9 Inhibitor, CVD, SC)
b. Ivabradine (R, Chronic Heart Failure):
c. Talimogene laherparepvec
d. Brodalumab (PhIII, moderate-to-severe plaque psoriasis and psoriatic arthritis, PhII, Asthma)
e. Omecamtiv mecarbil (PhIIb, Heartfailure, licensed from Cytokinetics)
f. Romosozumab (PhIII, co-developed with UCB, Postmenopausal Osteoporosis, PMO)
g. AMG 334 (PhIIb, CGRP receptor mAb)
h. Trebananib (PhIII, Ovarian Cancer):
i. AMG 416 (PhIII, secondary hyperparathyroidism in pt with CKD, velcalcetide)
• Failed in Clinical studies
• Biosimilars in Development
• AMGN’s Commercial Strategy

4. Biogen Idec – Growth from Newly Launched Products + Clinical Milestones of Novel Pipeline
• Near-Term Key Pipeline Candidates to Watch
• Hemophilia Franchise Offers Long-Term Opportunity
• Anti-CD20 franchise Continues to Grow through Label Expansion of GAZYVA
• NEUROLOGY: LEADERSHIP IN MS AND PORTFOLIO EXPANSION

5. Celgene – Innovative Strategies for Long Term Gains
• Development In Multiple Myeloma Franchise: Strengthening Pipeline
• Other Oncology Drugs
• Inflammation – Pipeline to start contributing to sales by 2015
• Other Products in Early stage for Long Term Growth

6. Gilead Sciences – Poised to Emerge as a Leader in HCV Treatment
• Sovaldi has made the way, Harvoni to take Lead
• Pipeline: Anti-viral Franchise — HCV
• Antiviral Franchise — HIV
• Cardiovascular Program
• Beyond Anti-Virals- Oncology
• Acquisitions In Last Two Years

7. Regeneron – Late-Stage Pipeline Potential – Accelerator for Further Growth
• Label expansion of E ylea in DME, BRVO, and Myopic CNV indication
• Late-Stage Pipeline
• REGN-Sanofi Collaboration

8. Vertex Pharma – From Large Volume Market to Niche Indications – Transformation has Paid
• Cystic Fibrosis: Success in G551D mutation to Repeat in Larger Population of del508 Mutation
• Small But Meaningful Addition in Other Mutations for KALYDECO monotherapy
• CF BACKGROUND
• Beyond CF Not a Priority

No. of Report pages: 90

Price of Report: $ 2000 (Single User Licence)

Purchase Report @ http://www.absolutereports.com/purchase/10437981

About Absolute Report:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.

Contact–

Mr. Ameya Pingaley

Absolute Reports

+1-408 520 9750

Email – sales@absolutereports.com

http://www.absolutereports.com

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.